Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of RAY1225 injection versus semaglutide in type 2 diabetes mellitus inadequately controlled on oral agents
CTR20252996Phase 3Active
- Sponsor
- Raynovent Biotech
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of RAY1225 in type 2 diabetes mellitus (T2DM), sponsored by Raynovent Biotech. Started Aug 2025; status: active.
02
Drugs
RAY1225
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252996.